Prabhu Sandeep, Mackin Vincent, McLellan Alex J A, Phan Tuong, McGlade Desmond, Ling Liang-Han, Peck Kah Y, Voskoboinik Alexandr, Pathik Bupesh, Nalliah Chrishan J, Wong Geoff R, Azzopardi Sonia M, Lee Geoffrey, Mariani Justin, Taylor Andrew J, Kalman Jonathan M, Kistler Peter M
Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
Baker IDI Heart and Diabetes Institute, Cabrini Health, Melbourne, Victoria, Australia.
J Cardiovasc Electrophysiol. 2017 Jan;28(1):13-22. doi: 10.1111/jce.13107. Epub 2016 Nov 29.
ELECTROPHYSIOLOGICAL AND HEMODYNAMIC ASSESSMENT.
DORMANT-AF STUDY: The significance of adenosine induced dormant pulmonary vein (PV) conduction in atrial fibrillation (AF) ablation remains controversial. The optimal dose of adenosine to determine dormant PV conduction is yet to be systematically explored.
ELECTROPHYSIOLOGICAL AND HEMODYNAMIC ASSESSMENT.
DORMANT-AF STUDY: Consecutive patients undergoing index AF ablation received 3 adenosine doses (12, 18, and 24 mg) in a randomized blinded order, immediately after pulmonary vein isolation (PVI). Electrophysiological (PR prolongation, AV block (AVB) and PV reconnection) and hemodynamic (BP) parameters were measured. A total, 339 doses (113/dose) assessed 191 PVs in 50 patients (66% male, 72% PAF, 52% hypertensive). Dormant PV conduction occurred in 28% of patients (16.5% [32] of PVs). All cases were associated with AVB (AVB: PV reconnection vs. no PV reconnection 100% vs. 83%, P = 0.007). AVB occurred more frequently at 24 mg versus 12 mg (92% vs. 82%, P = 0.019) but not versus 18 mg (91%, P = 0.62). AVB duration progressed between 12 mg (12.0 ± 8.9 seconds), 18 mg (16.1 ± 9.1 seconds, P = 0.001), and 24 mg (19.0 ± 9.3 seconds, P < 0.001) doses. MBP fell further at 24 mg (ΔMBP: 27 ± 12 mmHg) and 18 mg (26 ± 13 mmHg) doses compared to 12 mg (22 ± 10 mmHg vs., P < 0.001). A significant reduction in AVB in patients >110 kg (65% vs. 91% in 70-110 kg group, P < 0.001) in response to adenosine was seen.
ELECTROPHYSIOLOGICAL AND HEMODYNAMIC ASSESSMENT.
DORMANT-AF STUDY: An adenosine dose producing AVB is required to unmask dormant PV conduction. AVB is significantly reduced in patients >110 kg. Weight and dosing variability may in part explain the conflicting results of studies evaluating the clinical utility of adenosine in PVI.
电生理与血流动力学评估
腺苷诱发的隐匿性肺静脉(PV)传导在房颤(AF)消融中的意义仍存在争议。确定隐匿性PV传导的最佳腺苷剂量尚未得到系统探索。
电生理与血流动力学评估
接受初次AF消融的连续患者在肺静脉隔离(PVI)后,以随机双盲顺序接受3种腺苷剂量(12、18和24毫克)。测量电生理参数(PR间期延长、房室传导阻滞(AVB)和PV重新连接)和血流动力学参数(血压)。总共339剂(每种剂量113剂)评估了50例患者的191条PV(男性66%,阵发性房颤72%,高血压52%)。28%的患者出现隐匿性PV传导(PV的16.5%[32条])。所有病例均与AVB相关(AVB:PV重新连接与未重新连接分别为100%和83%,P = 0.007)。24毫克剂量时AVB的发生频率高于12毫克剂量(92%对82%,P = 0.019),但与18毫克剂量相比无差异(91%,P = 0.62)。AVB持续时间在12毫克(12.0±8.9秒)、18毫克(16.1±9.1秒,P = 0.001)和24毫克(19.0±9.3秒,P < 0.001)剂量之间呈进展性变化。与12毫克剂量(22±10毫米汞柱)相比,24毫克(平均血压下降:27±12毫米汞柱)和18毫克(26±13毫米汞柱)剂量时平均血压下降幅度更大(P < 0.001)。体重>110千克的患者对腺苷的反应中AVB显著降低(65%对70 - 110千克组的91%,P < 0.001)。
电生理与血流动力学评估
需要产生AVB的腺苷剂量来揭示隐匿性PV传导。体重>110千克的患者中AVB显著降低。体重和剂量变异性可能部分解释了评估腺苷在PVI中临床效用的研究结果相互矛盾的原因。